The publisher explores BioMarin’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (6 November 2020)
Model updates (5 August 2020)
Model updates (29 April 2020)
Model updates (26 February 2020)
Snapshot
- Overview - BioMarin’s ultra-rare diseases portfolio will maintain its solid growth and attractive orphan drug potential.
- Key themes - [1] BioMarin is set to double its pharmaceutical revenue over the forecast period [2] Approvals of Roctavian (valoctocogene roxaparvovec) and vosoritide are critical to long-term growth.
Model updates (6 November 2020)
- Palynziq forecast adjusted lower
- Vimizim forecast adjusted lower
- Roctavian forecast adjusted lower due to CRL.
Model updates (5 August 2020)
- Aldurazyme forecast adjusted higher
- Brineura forecast adjusted lower
- Palynziq forecast adjusted lower
- Kuvan forecast adjusted higher due to price increases in the US and product mix.
Model updates (29 April 2020)
- Vimizim forecast lowered due to impact from COVID-19
- Palynziq forecast lowered due to impact from COVID-19
- Valoctocogene roxaparvovec name changed to Roctavian.
Model updates (26 February 2020)
- Palynziq forecast adjusted higher due to continued growth due to switching from Kuvan
- Firdapse forecast removed due to sale to SERB.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview